OptiNose, Inc. (OPTN)
Chart Events
Performance Outlook
| Previous Close | 2.9200 |
| Open | 2.9300 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 1300 |
| Day's Range | 2.8100 - 2.9350 |
| 52 Week Range | 2.3200 - 5.1100 |
| Volume | 305,870 |
| Avg. Volume | 269,021 |
| Market Cap | 150.309M |
| Beta (5Y Monthly) | 0.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9380 |
| Earnings Date | May 05, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
- GlobeNewswire
Optinose to Present at the Cantor Virtual Global Healthcare Conference
YARDLEY, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 8:40 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of
- GlobeNewswire
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
YARDLEY, Pa., Aug. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 60,000 shares of its common stock to seven new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incent
- Zacks
OptiNose (OPTN) Reports Q2 Loss, Tops Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -2.33% and 5.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
